# Rabeprazole Extended-Release, 50 mg, Versus Esomeprazole, 40 mg, for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)

> **NCT00658775** · PHASE3 · COMPLETED · sponsor: **Eisai Inc.** · enrollment: 1069 (actual)

## Conditions studied

- Gastroesophageal Reflux Disease (GERD)

## Interventions

- **DRUG:** Rabeprazole sodium
- **DRUG:** Esomeprazole

## Key facts

- **NCT ID:** NCT00658775
- **Lead sponsor:** Eisai Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-02
- **Primary completion:** 2009-09
- **Final completion:** 2010-01
- **Target enrollment:** 1069 (ACTUAL)
- **Last updated:** 2015-12-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00658775

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00658775, "Rabeprazole Extended-Release, 50 mg, Versus Esomeprazole, 40 mg, for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00658775. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*